Sie sind hier: Lecture Download > Lecture Download Friday


Friday, December 2nd

MAC 2 - Molecular, genetic and mechanistic factors in aorticdiseases
Experimental models of aneurysm development and expansion - A. Busch, Germany
18FDG-PET imaging of unstable AAAs using microRNA signatures - N. Sakalihasan, Belgium
MAC 3 - Repair of the ascending aorta and the aortic arch
Frozen elephant trunk technique for aortic arch replacement - F. Beyersdorf, Germany
Advances in endografting of the aortic arch and its branches - S. Haulon, France
Ascending and arch branch endografts including carbon dioxide flushing to prevent air embolism - T. Kölbel, Germany
Early experience with a single branch device for the arch - M. Makaroun, USA
Initial clinical experience with an orthotopic endovascular solution for aortic arch pathology - M. Czerny, Germany
Hybrid treatment of the ascending aorta and arch in acute Type I dissection - H. G. Jakob, Germany

MAC 4 - Advances in EVAR and open repair for complex aneurysms and dissections
Results from a nationwide registry on scalloped thoracic stent grafts for short landing zones - C. Zeebregts, The Netherlands
Update on false lumen embolisation strategies in aortic dissections - T. Kölbel, Germany
Acute non-A non-B aortic dissection: definition, treatment and outcome - B. Rylski, Germany
The role of in situ fenestration in complex aortic repair - R. Kolvenbach, Germany

Special Lecture
Why the European qualification in vascular surgery (FEBVS) will be even more important in the future!
- A. Mansilha, Portugal

MAC 5 - Spinal cord protection in aortic surgery – evolving concepts to minimize the risk of paraplegia
Current strategies to prevent spinal cord ischemia in thoracoabdominal aortic aneurysm repair
G. W. Schurink, The Netherlands
MAC 6 - Advances in (P)EVAR for elective and ruptured AAA and the management of type I endoleaks
A comparison of percutaneous femoral access in EVAR versus open femoral access (PiERO): randomized controlled trial
- C. Zeebregts, The Netherlands
The fascial suture technique as closure procedure of the femoral arteries after EVAR – not only a bail out technique!
- M. Malina, Sweden
AAAs >55mm are more likely associated with hostile proximal neck: A potential need for reappraisal of diametre threshold to intervene in the EVAR era - A. Giannoukas, Greece
Endostapling in the prevention and treatment of type Ia endoleaks in the abdominal aorta (supported by an educational grant of Medtronic GmbH) - R. Kolvenbach, Germany
FEVAR for failed endovascular aortic repair - A. Assadian, Austria
Tipps and tricks to successfully treat juxtarenal ruptured AAA by EVAR - M. Malina, Sweden
Ruptured juxtarenal AAA are better treated by open surgery - J. Schmidli, Switzerland

Keynote Lecture
Prevalence and natural history of type II endoleaks – or: do we still midjudge a potentially dangerous condition?
- M. Makaroun, USA

MAC 7 - How to prevent and to treat type II endoleaks – a never ending story
How and when to do sac embolization during EVAR - A. Stella, Italy
Predictors of endoleak type II risk, in the era of prevention with aneurysm sac filling during EVAR - F. Grego, Italy
Are there any indications for preoperative embolisation of lumbar arteries and/or the IMA - L. Lönn, Denmark
Embolisation techniques of type II endoleaks (supported by an educational grant of Medtronic GmbH)
- A. Zimmermann, Germany

MAC 8 - Special session on radiation safety and team training
Ongoing radiation safety simulation training project: Update from Copenhagen, Denmark - L. Lönn, Denmark
Improving safety and work flow in the Hybrid OR: the HOT (Hybrid Operation Technician) concept - J. Gahlen, Germany
How to achieve optimal imaging in the Hybrid OR and to reduce radiation (according to the ALARA criteria) at the same time - S. Haulon, France
Optimal use of the Clarity system to reduce radiation for patients and staff - J. Tessarek, Germany

PAD 1 - Popliteal diseases
Current use of endorepair for popliteal aneurysms (PAA) - M. Makaroun, USA
Five year outcomes of surgical treatment for popliteal artery entrapment syndrome - N. Chakfe, France

PAD 2 - Hot topics on popliteal diseases, acute ischaemia and chronic limb ischaemia
Current status of controlled limb reperfusion - F. Beyersdorf, Germany
Acute lower limb ischaemia in patients with cancer - J. Scott, UK
Bioresorbable everolimus-eluting vascular scaffold for patients with peripheral artery disease (ESPRIT I): 2-year clinical and imaging results - F. Wolf, Austria
PAD 3 - Vascular calcifications – impact on treatment and outcomes
Biological mechanisms of severe vascular calcifications – do those patients need a more aggressive primary or secondary medical prevention strategy? - C. Liapis, Greece
The amount of aortic calcification is predictive for the rupture risk in AAA – is aortic calcification also predictive for other cardiovascular complications? - C. Zeebregts, The Netherlands
Techniques and results of infrainguinal endovascular recanalizations in heavily calcified peripheral arteries
- M. Fusaro, Germany

PAD 4 - Restenoses after open or endovascular recanalizations and complex primary peripheral lesions
Pathobiology of neointimal hyperplasia and restenosis: Lessons from cell biology and animal models
- M. Wildgruber, Germany
The impact of neoatherosclerosis after drug-eluting stents/balloons - M. Joner, Germany
In-stent-restenosis – are DEB the best way to go or should we use stentgrafts in this situation? - M. Fusaro, Germany
Which peripheral lesions should be treated primarily by DEB rather than plain balloons or stents? - I. van Herzeele, Belgium

Keynote Lecture
Transcriptomic insights into carotid artery plaque vulnerability - U. Hedin, Sweden

PAD 5 - Translational research of peripheral and carotid atherosclerosis
The long non-coding RNA MIAT regulates smooth muscle cell proliferation and macrophage activity in advanced atherosclerotic lesions - Y. Li, Sweden
Transcription factor Runx2 is induced in vascular aging and may promote age-related arterial stiffness
- I. Schellinger, Germany
PAD 6 - Periprocedural medication after open and endovascular PAD therapy
There is NO evidence for dual antiplatelet therapy in peripheral arterial disease interventions and the sense or nonsense of individual platelet function testing - G. de Borst, The Netherlands
Rationale and design of the VOYAGER Trial - H. Lawall, Germany
Intermediate dose of Tinzaparin for the treatment of superficial vein thrombosis: Results from a national multicentre study – the SEVEN Study - A. Giannoukas, Greece
Optimal medical adjuncts for distal leg bypasses – experiences from a dedicated and very experienced bypass surgeon
- A. Neufang, Germany